These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
473 related articles for article (PubMed ID: 17060849)
1. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Kröger N; Binder T; Zabelina T; Wolschke C; Schieder H; Renges H; Ayuk F; Dahlke J; Eiermann T; Zander A Transplantation; 2006 Oct; 82(8):1024-30. PubMed ID: 17060849 [TBL] [Abstract][Full Text] [Related]
2. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation. Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138 [TBL] [Abstract][Full Text] [Related]
3. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Morishima Y; Yabe T; Matsuo K; Kashiwase K; Inoko H; Saji H; Yamamoto K; Maruya E; Akatsuka Y; Onizuka M; Sakamaki H; Sao H; Ogawa S; Kato S; Juji T; Sasazuki T; Kodera Y; Biol Blood Marrow Transplant; 2007 Mar; 13(3):315-28. PubMed ID: 17317585 [TBL] [Abstract][Full Text] [Related]
4. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709 [TBL] [Abstract][Full Text] [Related]
5. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587 [TBL] [Abstract][Full Text] [Related]
6. Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. Giebel S; Nowak I; Wojnar J; Markiewicz M; Dziaczkowska J; Wylezol I; Krawczyk-Kulis M; Bloch R; Kusnierczyk P; Holowiecki J Transplant Proc; 2006; 38(1):287-91. PubMed ID: 16504727 [TBL] [Abstract][Full Text] [Related]
7. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population. Wu GQ; Zhao YM; Lai XY; Luo Y; Tan YM; Shi JM; Li L; Zheng WY; Zhang J; Hu XR; Jin AY; He JS; Xie WZ; Ye XJ; Cai Z; Lin MF; Huang H Bone Marrow Transplant; 2010 Oct; 45(10):1514-21. PubMed ID: 20173784 [TBL] [Abstract][Full Text] [Related]
8. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. De Santis D; Bishara A; Witt CS; Nagler A; Brautbar C; Slavin S; Christiansen FT Tissue Antigens; 2005 Jun; 65(6):519-28. PubMed ID: 15896199 [TBL] [Abstract][Full Text] [Related]
9. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. van der Meer A; Schaap NP; Schattenberg AV; van Cranenbroek B; Tijssen HJ; Joosten I Mol Immunol; 2008 Aug; 45(13):3631-8. PubMed ID: 18555529 [TBL] [Abstract][Full Text] [Related]
10. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E; Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053 [TBL] [Abstract][Full Text] [Related]
11. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Yabe T; Matsuo K; Hirayasu K; Kashiwase K; Kawamura-Ishii S; Tanaka H; Ogawa A; Takanashi M; Satake M; Nakajima K; Tokunaga K; Inoko H; Saji H; Ogawa S; Juji T; Sasazuki T; Kodera Y; Morishima Y; Biol Blood Marrow Transplant; 2008 Jan; 14(1):75-87. PubMed ID: 18158964 [TBL] [Abstract][Full Text] [Related]
12. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH Eur J Haematol; 2007 Apr; 78(4):338-46. PubMed ID: 17378893 [TBL] [Abstract][Full Text] [Related]
13. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation. Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C; Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295 [TBL] [Abstract][Full Text] [Related]
14. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Chen C; Busson M; Rocha V; Appert ML; Lepage V; Dulphy N; Haas P; Socié G; Toubert A; Charron D; Loiseau P Bone Marrow Transplant; 2006 Sep; 38(6):437-44. PubMed ID: 16892071 [TBL] [Abstract][Full Text] [Related]
15. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome. Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH Biol Blood Marrow Transplant; 2007 Jun; 13(6):734-44. PubMed ID: 17531784 [TBL] [Abstract][Full Text] [Related]
16. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM; Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058 [TBL] [Abstract][Full Text] [Related]
17. Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation? Willemze R; Ruggeri A; Purtill D; Rodrigues CA; Gluckman E; Rocha V; Best Pract Res Clin Haematol; 2010 Jun; 23(2):283-90. PubMed ID: 20837340 [TBL] [Abstract][Full Text] [Related]
18. Influence of killer cell immunoglobulin-like receptor genotypes on acute graft-vs-host disease after unrelated hematopoietic stem cell transplantation in Koreans. Kim SY; Choi HB; Yoon HY; Choi EJ; Cho B; Kim HK; Kim YJ; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Kim CC; Kim TG Tissue Antigens; 2007 Apr; 69 Suppl 1():114-7. PubMed ID: 17445182 [TBL] [Abstract][Full Text] [Related]
19. NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation. Denis L; Gagne K; Gueglio B; Kerdudou N; Milpied N; Simon P; Follea G; Bonneville M; Harousseau JL; Bignon JD Hum Immunol; 2005 May; 66(5):447-59. PubMed ID: 15935882 [TBL] [Abstract][Full Text] [Related]
20. Killer-cell immunoglobulin-like receptor ligand compatibility in the outcome of Finnish unrelated donor hematopoietic stem cell transplantation. Sivula J; Volin L; Porkka K; Vettenranta K; Itälä M; Partanen J; Turpeinen H Transpl Immunol; 2007 Jul; 18(1):62-6. PubMed ID: 17584604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]